| Company | Product | Type/ | Date Of | 1996 Sales | 1997 Sales | 1998 YTD |
| Indication* | 1st FDA | (M) | (M) | Sales (M)** | ||
| Approval | ||||||
| Agouron Pharmaceu- | Viracept | Small molecule HIV | 3/97 | — | $196 | $238*** |
| ticals Inc./Japan | protease inhibitor/ | |||||
| Tobacco Inc./Hoff- | AIDS in adults and | |||||
| mann-La Roche Inc. | children | |||||
| Amgen Inc. | Epogen | Erythropoietin/ | 6/89 | $1,071 | $1,161 | $641 |
| anemia in kidney | ||||||
| failure | ||||||
| Amgen Inc. | Neupogen | Granulocyte col- | 2/91 | $1,017 | $1,056 | $532 |
| ony stimulating | ||||||
| factor/ chemother- | ||||||
| apy-induced | ||||||
| neutropenia | ||||||
| BioChem Pharma Inc./ | Epivir | Nucleoside | 11/95 | C$429 | C$973 | C$570# |
| Glaxo Wellcome plc | (a.k.a. 3TC) | analogue/ AIDS | ||||
| Biogen Inc. | Avonex | Interferon-beta/ | 5/96 | $77 | $240 | $270 |
| multiple sclerosis | ||||||
| Centocor Inc./ | ReoPro | Chimeric monoclonal | 12/94 | $149 | $254 | $171## |
| Eli Lilly and Co. | antibody to GPIIb/IIIa | |||||
| platelet receptor/ | ||||||
| prevention of blood | ||||||
| clots in high-risk | ||||||
| angioplasty | ||||||
| Genentech Inc. | Activase | Tissue plasminogen | 11/87 | $284 | $261 | $155 |
| activator/ acute myo- | ||||||
| cardial infarction | ||||||
| Protropin/ | Human growth hor- | 10/85 | $218 | $224 | $166 | |
| Nutropin/ | mone/growth hormone | |||||
| Nutropin AQ | inadequacy in children | |||||
| Pulmozyme | Human DNase/ | 12/93 | $76 | $92 | $68 | |
| cystic fibrosis | ||||||
| Genzyme Corp. | Ceredase/ | Glucocerebrosidase/ | 4/91 | $265 | $333 | $192 |
| Cerezyme | Gaucher's disease | |||||
| Idec Pharmaceuticals | Rituxan | Chimeric pan-B mono- | 11/97 | — | $5.5 | $112@ |
| Corp./Genentech Inc./ | clonal antibody to CD20 | |||||
| F. Hoffmann-La Roche | antigen on B cells/ non- | |||||
| Ltd. | Hodgkin's lymphoma | |||||
| Immunex Corp. | Leukine | Granulocyte macro- | 3/91 | $43 | $53 | $48 |
| phage colony stimu- | ||||||
| lating factor/ autologous | ||||||
| bone marrow trans- | ||||||
| plantation | ||||||
| NOTES: | ||||||
| * The indication cited in the table corresponds to that for which the product received its first FDA approval. Some of these products have since then been approved for other indications, as well. If there is a family of products listed (i.e., Ceredase/Cerezyme or Protropin/Nutropin/Nutropin AQ), the approval date is for the first product of that group. | ||||||
| ** For most products in the table, 1998 sales figures are current as of the quarter ended 6/30. Several (Biogen Inc., Genentech Inc., and Immunex Corp.), are current as of the quarter ended 9/30/98. | ||||||
| *** Agouron Pharmaceuticals Inc.'s fiscal year ends 6/30/98. | ||||||
| # Sales figures for Epivir are quoted in Canadian dollars and represent worldwide sales by Glaxo Wellcome plc. BioChem Pharma got C$57.1M in royalties in fiscal 1996, C$124.1M in royalties in fiscal 1997 and C$72.2M for the 6 months ended 6/30/98. | ||||||
| ## Sales figures for ReoPro are end sales to customers as reported by marketing partner Eli Lilly and Co. In fiscal 1996, Centocor sold $88.7M of product to Lilly; in fiscal 1997, it sold $158.4M to Lilly; and for the 6 months ended 6/30/98, it sold $93.2M to Lilly. | ||||||
| @ Genentech Inc. reported Rituxan sales of $5.5M to year-end 1997 and a total of $111.9M ($103.3M in U.S. and $8.6M elsewhere) for the 9 months ended 9/30/98. Idec Pharmaceuticals Corp. sells bulk drug to Genentech and gets royalties from F. Hoffmann-La Roche Ltd.'s sales outside the U.S. | ||||||
